Financial crisis brings flurry of M&A work to lawyers
By Richard Szabo
|
Friday, 19 September 2008
When reports surfaced of Lehman Brother’s bankruptcy and the fall of
Merrill Lynch, Fannie Mae and Freddie Mac in the US, it seemed like market activity had slowed. But figures released by Mergermarket show otherwise, indicating a flurry of strategic North American M&A activity.
There were 28 deals totalling US$15.4bn in the week ending on 14 September 2008. By comparison, the week before had 55 M&A deals valued at just US$4.3bn. The largest deals included Altria Group's acquisition of UST (US$11.5bn), Conoco's acquisition of Origin Energy’s coal steam gas assets (US$7.8bn), Coca-Cola’s acquisition of China Huiyuan Juice Group (US$2.4bn) and King Pharmaceuticals’ acquisition of Alpharma (US$1.2bn).
US
Altria Group UST takeover
US$11.5bn
• Altria maintains a portfolio of leveraged and direct finance leases and as of 31 December 2007 it held a 28.6% stake in SABMiller
• Equity value of the transaction is about US$10.3bn before assumption of debt.
• Terms call for Altria to pay US$69.5 per share, a premium of 2.9%
Bidder financial advisers: Centerview Partners, Goldman Sachs, JPMorgan
Bidder legal advisers: Arnold & Porter, Hunton & Williams, Sutherland Asbill & Brennan
Seller financial advisers: Citigroup, Perella Weinberg Partners
Seller legal advisers: Skadden Arps Slate Meagher & Flom, Sullivan & Cromwell, Weil Gotshal & Manges (advising Citigroup) |
Source: Mergermarket
US/Australia
ConocoPhillips Origin Energy takeover
US$7.8bn
• ConocoPhillips formed a joint venture, acquiring a 50% stake in coal seam gas assets of Origin Energy
• ConocoPhillips will make initial payment of US$4.9bn, with contributions of US$946.2m and US$493.7m
Bidder financial advisor: Credit Suisse
Bidder legal advisor: Allens Arthur Robinson, Wachtell Lipton Rosen & Katz
Seller financial advisor: Grant Samuel, Macquarie Group
Seller legal advisor: Clayton Utz |
Source: Mergermarket
US
King Pharmaceuticals Alpharma acquisition
US$1.2bn
• Alpharma received a tender offer from King Pharmaceuticals at US$37 per share cash, a 54% premium on its current value
• Equity value is about US$1.5bn not including cash
• Deal expected to close by end of year
Seller financial advisor: Bank of America Securities
Bidder financial advisor: Credit Suisse; Wachovia Securities
Seller legal advisor: Simpson Thacher & Bartlett
Bidder legal advisor: Dewey & LeBoeuf; Jones Day |
Source: Mergermarket